Media

Intervacc’s variation application approved by VMD

Tribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies

Vicore publishes the Annual Report for 2024

Aprea Therapeutics reports fourth quarter and full year 2024 financial results and provides a business update

Oncorena receives FDA approval to initiate studies in the US

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Oncopeptides receives first order of Pepaxti in Italy

HelloBetter Secures Over €6 Million to Accelerate International Expansion and AI Development

Hemab Therapeutics Announces Start of Velora Pioneer, a Phase 1/2 Clinical Trial Investigating HMB-002 for the Treatment of Von Willebrand Disease

Vicore Pharma Holding AB – Year-end report 2024